Analgesic composition of topically applied nonsteroidal antiinflammatory drugs and opioids
- Summary
- The attractiveness of this combinations is their propensity to suppress the expression and function of proteins involved in inflammatory and neuropathic pain and in the same time to activate the antinociceptive mu opiod system involved in pain relief. Targeting the different system, pro-nociceptive and anti-nociceptive, result in summation of the analgesic effects.
- Technology Application
- The European neuropathic pain market is characterized by a particularly high level of unmet need for effective therapeutics due to the under-utilization of anti-depressants, the lack of opioid availability, commonly used to treat neuropathic pain in the U.S. and certain European country-markets, but not others. This under-utilization stems primarily from a lack of awareness about the potential utility of these drugs in neuropathic pain treatment and concerns about opioid addiction. By 2015, the market for drug treatment of major neuropathic pain conditions in the five major European pharmaceutical markets - France, Germany, Italy, Spain and the UK -will reach $3.8 billion. Given this substantial commercial potential and a patient population approaching 13 million in Europe alone, upcoming products for the treatment of Neuropathic Back Pain, Diabetic Neuropathy, Post-Herpetic Neuralgia, Trigeminal Neuralgia, and HIV / AIDS Neuropathy are vigorously being research and developed by pharmaceutical companies . None of the currently available pain-treatment options is adequate for the control of chronic pain. Some options are nonspecific. They therefore may deliver some relief from pain, but their nonspecific activities give rise to undesirable and sometimes painful side effects
- Type of Cooperation
- Sale, License agreement
- Countries
- Germany, UK, France, Italy, Sweden, Swiss,Ireland, Canada, Australia. Pending USA, India
- Supplementary Information
- Inventor: Frey, Andreas | Neutra, Marian R. | Robey, Frank A.
Priority Number: US6086881A
IPC Current: A61K000916 | A61K000951 | A61K0039385 | A61P003704 | C07K001416
US Class: 4241941 | 42400153 | 42400169 | 42419611 | 42419711 | 530324
Assignee Applicant: Children's Medical Center Corporation,Boston
Title: Spatially aligned conjugated composition having a thioether bond linkage
Usefulness: Spatially aligned conjugated composition having a thioether bond linkage
Summary: The composition is useful as an immunogen and as a vaccine. The composition induces an immune response against a virus, or a bacterium. The composition especially induces an immune response against rickettsiae, chlamydiae, mycoplasms, protozoa, fungal or parasitic infectious agents (all claimed). It is also useful as a diagnostic tool in any assay involving antibodies specific for the antigen or hapten indicative of an infectious agent. The composition may be employed for its spatial orientation and structural configuration properties in order to play any role in determining or evaluating the biological activity of novel peptides, proteins, or other pharmacological agents that are ostensibly biologically active.
Novelty: New spatially aligned conjugated composition having a thioether bond linkage, useful as an immunogen or vaccine against virus, bacteria (e.g. rickettsiae or chlamydiae), protozoa, fungal or parasitic infectious agents
- Industry
- Biomedical
- Sub Category
- Medical Composition
- Application No.
- European Patent No.60 2007 002 154.5-08
- Country/Region
- Denmark
For more information, please click Here
